SELLAS Life Sciences (SLS) Common Equity (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Common Equity data on file, last reported at $107.4 million in Q1 2026.

• On a quarterly basis, Common Equity rose 286.94% year-over-year to $107.4 million in Q1 2026; TTM through Mar 2026 was $107.4 million, a 286.94% increase from a year earlier, with the FY2025 full-year figure at $70.9 million, up 648.77% from the prior year.
• Common Equity for Q1 2026 stood at $107.4 million, up from $70.9 million in the prior quarter.
• Over the last five years, Common Equity for SLS reached as high as $107.4 million in Q1 2026 and fell as low as -$8.0 million in Q4 2023.
• Historically, Common Equity has averaged $21.3 million across 5 years, with a median of $12.6 million in 2022.
• Across the five-year window, Common Equity sank 264.42% in 2023 and surged 797.67% in 2025, its largest moves.
• Year by year, Common Equity stood at $4.9 million in 2022, then sank by 264.42% to -$8.0 million in 2023, then soared by 218.67% to $9.5 million in 2024, then surged by 648.77% to $70.9 million in 2025, then surged by 51.56% to $107.4 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $107.4 million in Q1 2026, $70.9 million in Q4 2025, and $45.6 million in Q3 2025.